{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:38:35Z","timestamp":1793191115068,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12325-016-0430-6","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T02:08:34Z","timestamp":1477620514000},"page":"2188-2199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Assessing Short-term Deterioration in Maintenance-na\u00efve Patients with COPD Receiving Umeclidinium\/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials"],"prefix":"10.1007","volume":"33","author":[{"given":"M. Reza","family":"Maleki-Yazdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Tombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Fahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Naya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,28]]},"reference":[{"key":"430_CR1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1465-9921-10-59","volume":"10","author":"CR Jenkins","year":"2009","unstructured":"Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol\/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.","journal-title":"Respir Res"},{"key":"430_CR2","doi-asserted-by":"crossref","first-page":"14003","DOI":"10.1038\/npjpcrm.2014.3","volume":"24","author":"T Troosters","year":"2014","unstructured":"Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003.","journal-title":"NPJ Prim Care Respir Med"},{"key":"430_CR3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1183\/09031936.00127809","volume":"36","author":"T Troosters","year":"2010","unstructured":"Troosters T, Celli B, Lystig T, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT\u00ae trial. Eur Respir J. 2010;36:65\u201373.","journal-title":"Eur Respir J"},{"key":"430_CR4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12325-015-0218-0","volume":"32","author":"GT Ferguson","year":"2015","unstructured":"Ferguson GT, Flezar M, Korn S, et al. Efficacy of tiotropium\u00a0+\u00a0olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32:523\u201336.","journal-title":"Adv Ther"},{"key":"430_CR5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4104\/pcrj.2010.00059","volume":"20","author":"MT Dransfield","year":"2010","unstructured":"Dransfield MT, Bailey W, Crater G, et al. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2010;20:46.","journal-title":"Prim Care Respir J"},{"key":"430_CR6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","volume":"2","author":"PW Jones","year":"2005","unstructured":"Jones PW. St. George\u2019s respiratory questionnaire: MCID. COPD. 2005;2:75\u20139.","journal-title":"COPD"},{"key":"430_CR7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-12-40","volume":"12","author":"M Westwood","year":"2011","unstructured":"Westwood M, Bourbeau J, Jones PW, et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.","journal-title":"Respir Res"},{"key":"430_CR8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ijn.12265","volume":"21","author":"S Wilke","year":"2015","unstructured":"Wilke S, Spruit MA, Wouters EF, et al. Determinants of 1-year changes in disease-specific health status in patients with advanced chronic obstructive pulmonary disease: a 1-year observational study. Int J Nurs Pract. 2015;21:239\u201348.","journal-title":"Int J Nurs Pract"},{"key":"430_CR9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111\u201324.","journal-title":"COPD"},{"key":"430_CR10","unstructured":"GOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease http:\/\/www.goldcopd.com\/ . Accessed Aug 2015."},{"key":"430_CR11","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","volume":"108","author":"MR Maleki-Yazdi","year":"2014","unstructured":"Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752\u201360.","journal-title":"Respir Med"},{"key":"430_CR12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","volume":"2","author":"M Decramer","year":"2014","unstructured":"Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24\u00a0weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472\u201386.","journal-title":"Lancet Respir Med"},{"key":"430_CR13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23:932\u201346.","journal-title":"Eur Respir J"},{"key":"430_CR14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1465-9921-12-54","volume":"12","author":"D Renard","year":"2011","unstructured":"Renard D, Looby M, Kramer B, et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res. 2011;12:54.","journal-title":"Respir Res"},{"issue":"1","key":"430_CR15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/COPD.S101612","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy B, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11(1):1413\u201324.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"430_CR16","first-page":"A1","volume":"70","author":"I Naya","year":"2015","unstructured":"Naya I, Tombs L, Jones P. Short-term clinically important deterioration predicts long-term clinical outcome in copd patients: a post hoc analysis of the torch trial. Thorax. 2015;70:A1\u2013254.","journal-title":"Thorax"},{"key":"430_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/COPD.S27480","volume":"7","author":"C Tantucci","year":"2012","unstructured":"Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"430_CR18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","volume":"374","author":"M Decramer","year":"2009","unstructured":"Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171\u20138.","journal-title":"Lancet"},{"key":"430_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","volume":"71","author":"Y Oba","year":"2016","unstructured":"Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15\u201325.","journal-title":"Thorax"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0430-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T22:18:46Z","timestamp":1498342726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0430-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,28]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0430-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,28]]}}}